Cephalosporins in the Treatment of Community-Acquired Upper and Lower Respiratory Tract Infections Based on Antimicrobial Resistance Data from Russia

Clinical Microbiology and Antimicrobial Chemotherapy. 2010; 12(2):146-153

​ Fokin A.A.
cephalosporins acute otitis media acute rhinosinusitis acute tonsillitis/pharyngitis COPD community-acquired pneumonia
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2010; 12(2):146-153

Abstract

Beta-lactams remain one of the most commonly used antimicrobial classes in the treatment of community-acquired respiratory tract infections worldwide. Among them, cephalosporins take one of the main places because of their broad spectrum of activity against many important pathogens and favorable safety profiles. This review considers possibilities of the use of different cephalosporins based on their pharmacokinetic and pharmacodynamic properties as well as Russian data on antimicrobial resistance, in the treatment of patients with the most significant community-acquired upper and lower respiratory tract infections.

  • 1. Schappert S.M. Office visits for otitis media: United States, 1975–1990. Adv Data Vital Health Stat 1992; 214:1-20.
  • 2. Berman S. Otitis media in children. N Engl J Med 1995; 332:1560-5.
  • 3. National Institute of Allergy and Infectious Diseases. Available at: http://www3.niaid.nih.gov/.
  • 4. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am J Resp Crit Care Med 2001; 163:1730-54.
  • 5. Ewig S. Community-acquired pneumonia. Epidemiology, risk and prognosis. Eur Respir Mon. 1997; 3:13-35.
  • 6. Barlow G.D., Lamping D.L., Davey P.G., Nathwani D. Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians and policy-makers. Lancet Infect Dis 2003; 3:476-88.
  • 7. Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Клин микробиол антимикроб химиотер 2006; 8(1):54-86.
  • 8. Klein J.O. Otitis media. Clin Infect Dis 1994; 19:823–33.
  • 9. Каманин Е.И., Стецюк О.У. Инфекции верхних дыхательных путей и ЛОР-органов. В кн.: Практическое руководство по антиинфекционной химиотерапии. Под ред. Страчунского Л.С., Белоусова Ю.Б., Козлова С.Н. - Смоленск: МАКМАХ, 2007. - С. 248- 57.
  • 10. Cherry D.K., Woodwell D.A. National ambulatory medical care survey: 2000 Summary. Adv Data 2002; 328:1– 324.
  • 11. McCaig L.F., Besser R.E., Hughes J.M. Trends in antimicrobial prescribing rates for children and adolescents. JAMA 2002; 287:3096-102.
  • 12. Rosenfeld R.M., Vertrees J.E., Carr J., et al. Clinical efficacy of antimicrobial drugs for acute otitis media: metaanalysis of 5400 children from thirty-three randomized trials. J Pediatr 1994; 124(3):431.
  • 13. Appelman C., Bossen P., Dunk J., et al. Guideline Dutch College of Family Doctors acute otitis media. Utrecht: Dutch College of Family Doctors, 1990.
  • 14. Rovers M., Schilder A., Zielhuis G., et al. Otitis media. Lancet 2004; 363:465-73.
  • 15. Le Saux N., Gaboury I., Baird M., et al. A randomized double-blind controlled non-inferiority trial of placebo versus amoxicillin for clinically diagnosed acute otitis media in children 6 months to 5 years. CMAJ 2005; 172(3):335-41.
  • 16. Damoiseaux R., van Balen F., Hoes A., et al. Primary care based randomised, double blind trial of amoxicillin versus placebo for acute otitis media in children aged under 2 years. BMJ 2000; 320:350-54.
  • 17. Van Zuijlen D.A., Schilder A.G., Van Balen F.A., et al. National differences in acute mastoiditis: relationship to prescribing patterns of antibiotics for acute otitis media? Pediatr Infect Dis J 2001; 20:140-4.
  • 18. Kilpi T., Anttila M., Kallio M.J., et al. Severity of childhood bacterial meningitis: duration of illness before diagnosis. Lancet 1991; 338:406-9.
  • 19. New York Region Otitis Project. Observation Option Toolkit for Acute Otitis Media. Publication No. 4894. New York, NY: State of New York, Department of Health; 2002.
  • 20. Rosenfeld R.M. Observation option toolkit for acute otitis media. Int J Pediatr Otorhinolaryngol 2001; 58:1-8.
  • 21. American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media, 2004. Diagnosis and management of acute otitis media. Pediatrics 2004; 113:1451-65.
  • 22. Козлов С.Н. Цефалоспорины. Под ред. Сино­пальникова А.И., Козлова Р.С. - М.: Премьер МТ, Наш Город, 2007. - С. 68-83.
  • 23. Wise R., Andrews J.M., Ashby J.P., et al. Ceftibuten – in vitro activity against respiratory pathogens, beta-lactamase stability and mechanism of action. J Antimicrob Chemother 1990; 26(2):209-13.
  • 24. Aracil B., Gуmez-Garcйs J.L., Alуs J.I., et al. Sensitivity of Haemophilus influenzae isolates in Spain to 17 oral antibiotics. Enferm Infecc Microbiol Clin 2003; 21(3):131-6.
  • 25. Проект ПеГАС-II. 2004-2005 гг. Неопубликованные данные. НИИ Антимикробной Химиотерапии ГОУ ВПО «СГМА Росздрава».
  • 26. Craig W.A., Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15(3):255-9.
  • 27. Scaglione F., Demartini G., Dugnani S., et al. Interpretation of middle ear fluid concentrations of antibiotics: comparison between ceftibuten, cefixime and azithromycin. Br J Clin Pharmacol 1999; 47(3):267-71.
  • 28. Barr W.H.; Affrime M.; Lin C.C.; Batra V. Pharmacokinetics of ceftibuten in children. Pediatr Infect Dis J 1995; 14(7 Suppl):S93-101.
  • 29. Barr W.H.; Lin C.C.; Radwanski E., et al. The pharmacokinetics of ceftibuten in humans. Diagn Microbiol Infect Dis 1991; 14(1):93-100.
  • 30. Wise R., Nye K., O’Neill P., et al. Pharmacokinetics and tissue penetration of ceftibuten. Antimicrob Agents Chemother 1990; 34(6):1053-5.
  • 31. Green S.M., Rothrock S.G. Single-dose intramuscular ceftriaxone for acute otitis media in children. Pediatrics 1993; 91:23-30.
  • 32. Leibovitz E., Piglansky L., Raiz S., et al. Bacteriologic and clinical efficacy of one day vs. three day intramuscular ceftriaxone for treatment of nonresponsive acute otitis media in children. Pediatr Infect Dis J 2000; 19:1040-50.
  • 33. Lethbridge-Cejku M., Rose D., Vickerie J. Summary health statistics for U.S. adults: National Health Interview Survey, 2004. National Center for Health Statistics. Vital Health Stat 2006; 10(228):19-22.
  • 34. Anand V.K. Epidemiology and economic impact of rhinosinusitis. Ann Otol Rhinol Laryngol 2004; 193(Suppl):3-5.
  • 35. Sinus and Allergy Health Partnership (SAHP). Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004; 130(Suppl):1-45.
  • 36. Slavin R.G., Spector S.L., Bernstein I.L., et al. The diagnosis and management of sinusitis: a practice parameter update. J Allergy Clin Immunol 2005; 116(6):13-47.
  • 37. Gwaltney J.M. Jr, Scheld W.M., Sande M.A., et al. The microbial etiology and antimicrobial therapy of adults with acute communityacquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies. J Allergy Clin Immunol 1992; 90:457-62.
  • 38. Berg O., Carenfelt C., Kronvall G. Bacteriology of maxillary sinusitis in relation to character of inflammation and prior treatment. Scand J Infect Dis 1988 ;20:511-6.
  • 39. Gwaltney J., Syndor A., Sande M. Etiology and antimicrobial treatment of acute sinusitis. Otol Rhinol Layrngol 1981; 90:68-71.
  • 40. Brook I. Microbiology and management of sinusitis. J Otolaryngol 1996; 25:249-56;
  • 41. Каманин Е.И., Отвагин И.В., Козлов Р.С. и др. Острый бактериальный синусит. Клин микробиол антимикроб химиотер 2008; 10(1):34-45.
  • 42. Rosenfeld R.M., Andes D., Bhattacharyya N., et al. Clinical practice guideline: Adult sinusitis. Otolaryngology–Head and Neck Surgery 2007; 137:S1-S31.
  • 43. Scheid D.C., Hamm R.M. Acute bacterial rhinosinusitis in adults: part II. Treatment. Am Fam Physician 2004; 70(9):1697-704.
  • 44. Williams J.W., Aguilar C., Cornell J., et al. Antibiotics for acute maxillary sinusitis. Cochrane Database Syst Rev 2003; (2):CD000243.
  • 45. Pichichero M.E., Doern G.V., Kuti J.L., et al. Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children. Paediatr Drugs 2008; 10(6):391-7.
  • 46. Krumpe P., Lin C.C., Radwanski E. The penetration of ceftibuten into the respiratory tract. Chest 1999; 116(2):369-74.
  • 47. Pichichero M.E. Group A streptococcal tonsillopharyngitis: cost-effective diagnosis and treatment. Ann Emerg Med 1995;25: 390-403.
  • 48. Bisno A.L., Gerber M.A., Gwantley J.M., Kaplan E.L., Schwartz R.H. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Clin Infect Dis 2002;35: 113-25.
  • 49. Casey J.R., Pichichero M.E. Meta-analysis of cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis in children. Pediatrics 2004; 113(4):866-82.
  • 50. Adam D., Hostalek U., Troster K. 5-day therapy of bacterial pharyngitis and tonsillitis with cefixime: comparison with 10-day treatment with penicillin V [in German]. Cefixime Study Group. Klin Padiatr 1996; 208:310-3.
  • 51. Boccazzi A., Tonelli P., DeAngelis M., et al. Short course therapy with ceftibuten versus azithromycin in pediatric streptococcal pharyngitis. Pediatr Infect Dis J 2000; 19:963-7.
  • 52. Tack K.J., Henry D.C., Gooch W.M., et al. Five-day cefdinir treatment for streptococcal pharyngitis. Cefdinir Pharyngitis Study Group. Antimicrob Agents Chemother 1998; 42:1073-5.
  • 53. Pichichero M.E., Gooch W.M., Rodriguez W., et al. Effective short-course treatment of acute group A betahemolytic streptococcal tonsillopharyngitis: ten days of penicillin vs. 5 days or 10 days of cefpodoxime therapy in children. Arch Pediatr Adolesc Med 1994; 148:1053-60.
  • 54. Drago L., Ripa S., Zampaloni C., et al. Activity of ceftibuten, cefaclor, azithromycin, clarithromycin, erythromycin and telithromycin against Streptococcus pyogenes clinical isolates with different genotypes and phenotypes. Chemotherapy. 2005; 51(5):268-71.
  • 55. Block S.L., Hedrick J.A., Tyler R.D. Comparative study of the effectiveness of cefixime and penicillin V for the treatment of streptococcal pharyngitis in children and adolescents. Pediatr Infect Dis J. 1992; 11:919-25.
  • 56. Adam D., Hostalek U., Troster K. Five-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillinVtherapy. Cefixime Study Group Infection 1995; 23(2):S83-86.
  • 57. Pichichero M.E., McLinn S.E., Gooch W.M. III, et al. Ceftibuten vs. penicillin V in group A beta-hemolytic streptococcal pharyngitis. Pediatr Infect Dis J 1995; 14: S102-107.
  • 58. Nemeth M.A., Gooch W.M. III, Hedrick J., et al. Comparison of cefdinir and penicillin for the treatment of pediatric streptococcal pharyngitis. Clin Ther 1999; 21:1525-32.
  • 59. Kardas P., Ratajczyk-Pakalska E. Patient adherence in respiratory tract infections: ceftibuten versus other antibiotics (PARTICULAR study). Pol Merkur Lekarski 2001; 10(60):445-9.
  • 60. Maioli E., Marchese A., Roveta S. In vitro activity of ceftibuten at sub-inhibitory concentrations in comparison with other antibiotics against respiratory and urinary tract pathogens 2007; 19(2):152-60.
  • 61. Roche N., Huchon G. Epidemiology of chronic obstructive pulmonary disease. Rev Prat 2004; 54:1408-13.
  • 62. Anto J.M., Vermeire P., Vestbo J., et al. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17:982-94.
  • 63. Синопальников А.И., Романовских А.Г. Инфекционное обострение хронической обструктивной болезни легких. Под ред. Синопальникова А.И., Козлова Р.С. - М.: Премьер МТ, Наш Город, 2007. - С. 267-94.
  • 64. McAdoo M.A., Rice K., Gordon G.R., et al. Comparison of ceftibuten once daily and amoxicillin-clavulanate three times daily in the treatment of acute exacerbations of chronic bronchitis. Clin Ther 1998; 20(1):88-100.
  • 65. Ziering W., McElvaine P. Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbation of chronic bronchitis. Infection 1998; 26(1):68-75.
  • 66. Guest N., Langan C.E. Comparison of the efficacy and safety of a short course of ceftibuten with that of amoxycillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. Int J Antimicrob Agents 1998; 10(1):49-54.
  • 67. Сидоренко С.В., Козлов С.Н. Группа цефалоспоринов. В кн.: Практическое руководство по антиинфекционной химиотерапии. Под ред. Страчунского Л.С., Белоусова Ю.Б., Козлова С.Н. - Смоленск: МАКМАХ, 2007. - С. 77-83.
  • 68. Синопальников А.И. Внебольничная пневмония. Под ред. Синопальникова А.И., Козлова Р.С. - М.: Премьер МТ, Наш Город, 2007. - С. 295-333.
  • 69. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Инфекции нижних дыхательных путей. Практическое руководство по антиинфекционной химиотерапии. Под ред. Страчунского Л.С., Белоусова Ю.Б., Козлова С.Н. - Смоленск: МАКМАХ, 2007. - С. 258-66.
  • 70. Fernбndez P., San Martнn L. Community acquired pneumonia: from intravenous to oral cephalosporin sequential therapy. Rev Med Chil 2000; 128(3):267-72.
  • 71. Jewesson P. Economic impact of intravenous-to-oral antibacterial stepdown therapy. Clin. Drug Invest 1996; 11(2):1-9.
  • 72. Jewesson P. Cost-effectiveness and value of an IV switch. PharmacoEconomics 1994; 5(2):20-6.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared